Melkart Duo (Metformin Hydrochloride, Vildagliptin)

Melkart Duo is indicated for the management of type 2 diabetes mellitus, a chronic metabolic disorder characterized by hyperglycemia.

• Type 2 diabetes mellitus: improves overall glycemic control as monotherapy or in combination with other antidiabetic agents.
• Adjunct therapy with metformin: provides additional glucose lowering when metformin alone is insufficient.
• Combination therapy: reduces fasting and postprandial glucose levels in patients requiring dual‑mechanism treatment.

• Metformin Hydrochloride reduces hepatic gluconeogenesis and enhances peripheral insulin sensitivity, thereby decreasing basal glucose production. Vildagliptin selectively inhibits the enzyme dipeptidyl peptidase‑4 (DPP‑4), which prolongs the activity of endogenous incretin hormones (GLP‑1 and GIP). The increased incretin effect promotes glucose‑dependent insulin secretion and suppresses glucagon release, together providing complementary glucose‑lowering actions.

The combination of metformin and vildagliptin may be associated with several adverse reactions.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Diarrhea: frequent loose stools.
• Abdominal discomfort: cramps or pain.
• Headache: mild tension‑type headache.
• Dizziness: transient light‑headedness.

Serious or Rare Side Effects

• Lactic acidosis: rare but life‑threatening metabolic complication.
• Severe hypoglycemia: especially when combined with insulin or sulfonylureas.
• Acute pancreatitis: sudden abdominal pain with elevated enzymes.
• Stevens‑Johnson syndrome or toxic epidermal necrolysis: severe skin reactions.
• Hepatic failure: marked liver enzyme elevation and dysfunction.

Before initiating Melkart Duo, several safety considerations should be evaluated.

• Renal function assessment: ensure eGFR ≥30 mL/min/1.73 m² before use.
• Hepatic impairment: avoid in patients with significant liver disease.
• Risk of lactic acidosis: contraindicated in conditions predisposing to hypoxia.
• Monitor blood glucose: adjust dose if hypoglycemia occurs.
• Use with caution in elderly: increased susceptibility to dehydration and renal decline.
• Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Melkart Duo can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

• Severe renal impairment: metformin accumulation may cause lactic acidosis.
• Concomitant use of other DPP‑4 inhibitors: additive effect increases risk of pancreatitis.
• Excessive alcohol intake: heightens risk of metformin‑related lactic acidosis.
• Iodinated contrast agents: temporary discontinuation of metformin is recommended.
• Hepatic failure: both components may exacerbate liver dysfunction.

Moderate Interactions (Monitor Closely)

• Sulfonylureas or insulin: increased risk of hypoglycemia, monitor glucose levels.
• Cimetidine or other OCT2 inhibitors: may raise metformin plasma concentrations.
• Diuretics (loop or thiazide): affect renal clearance, watch renal function.
• ACE inhibitors or ARBs: combined effect on renal perfusion, assess kidney function.
• Beta‑blockers: may mask hypoglycemia symptoms, educate patient.